Installation
About
Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' / 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (South Africa: Cmax) - is implemented as well.
| github.com/Helmut01/replicateBE | |
| Bug report | File report |
Key Metrics
Downloads
| Yesterday | 37 0% |
| Last 7 days | 53 +8% |
| Last 30 days | 286 -9% |
| Last 90 days | 1.103 +41% |
| Last 365 days | 3.625 -21% |